TY - JOUR
T1 - Genetic disarray follows mutant KLF1-E325K expression in a congenital dyserythropoietic anemia patient
AU - Varricchio, Lilian
AU - Planutis, Antanas
AU - Manwani, Deepa
AU - Jaffray, Julie
AU - Beau Mitchell, W.
AU - Migliaccio, Anna Rita
AU - Bieker, James J.
N1 - Publisher Copyright:
©2019 Ferrata Storti Foundation
PY - 2019
Y1 - 2019
N2 - C ongenital dyserythropoietic anemia type IV is caused by a heterozygous mutation, Glu325Lys (E325K), in the KLF1 transcription factor. Molecular characteristics of this disease have not been clarified, partly due to its rarity. We expanded erythroid cells from a patient’s peripheral blood and analyzed its global expression pattern. We find that a large number of erythroid pathways are disrupted, particularly those related to membrane transport, globin regulation, and iron utilization. The altered genetics lead to significant deficits in differentiation. Glu325 is within the KLF1 zinc finger domain at an amino acid critical for site specific DNA binding. The change to Lys is predicted to significantly alter the target site recognition sequence, both by subverting normal recognition and by enabling interaction with novel sites. Consistent with this, we find high level ectopic expression of genes not normally present in the red cell. These altered properties explain patients’ clinical and phenotypic features, and elucidate the dominant character of the mutation.
AB - C ongenital dyserythropoietic anemia type IV is caused by a heterozygous mutation, Glu325Lys (E325K), in the KLF1 transcription factor. Molecular characteristics of this disease have not been clarified, partly due to its rarity. We expanded erythroid cells from a patient’s peripheral blood and analyzed its global expression pattern. We find that a large number of erythroid pathways are disrupted, particularly those related to membrane transport, globin regulation, and iron utilization. The altered genetics lead to significant deficits in differentiation. Glu325 is within the KLF1 zinc finger domain at an amino acid critical for site specific DNA binding. The change to Lys is predicted to significantly alter the target site recognition sequence, both by subverting normal recognition and by enabling interaction with novel sites. Consistent with this, we find high level ectopic expression of genes not normally present in the red cell. These altered properties explain patients’ clinical and phenotypic features, and elucidate the dominant character of the mutation.
UR - http://www.scopus.com/inward/record.url?scp=85076065980&partnerID=8YFLogxK
U2 - 10.3324/haematol.2018.209858
DO - 10.3324/haematol.2018.209858
M3 - Article
C2 - 30872368
AN - SCOPUS:85076065980
SN - 0390-6078
VL - 104
SP - 2372
EP - 2381
JO - Haematologica
JF - Haematologica
IS - 12
ER -